Suppr超能文献

用葡醛内酯治疗甲氨蝶呤中毒的患者。

Glucarpidase to combat toxic levels of methotrexate in patients.

机构信息

Department of Biochemistry, Midwestern University, IL, USA.

出版信息

Ther Clin Risk Manag. 2012;8:403-13. doi: 10.2147/TCRM.S30135. Epub 2012 Nov 22.

Abstract

In January 2012, glucarpidase (Voraxaze(®)) received approval from the US Food and Drug Administration for intravenous treatment of toxic plasma methotrexate concentrations due to impaired renal clearance. Methotrexate, an antifolate agent, has been used for over 60 years in the treatment of various cancers. High-dose methotrexate has been particularly useful in the treatment of leukemias and lymphomas. However, even with aggressive hydration and urine alkalinization, such regimens can lead to acute renal dysfunction, as indicated by decreases in urine production and concomitant increases in blood urea nitrogen and serum creatinine levels. Because methotrexate is largely excreted by the kidneys, this can greatly potentiate tissue damage. Toxic levels of blood methotrexate can be rapidly and effectively decreased by intravenous administration of glucarpidase. Glucarpidase is a recombinant form of carboxypeptidase G2, a bacterial enzyme that rapidly cleaves methotrexate to form the amino acid glutamate and 2,4-diamino-N(10)-methylpteroic acid. Catabolites of methotrexate are much less toxic than the parent compound, and are primarily excreted by hepatic mechanisms. Glucarpidase has been available on a compassionate basis since the 1990s, and a variety of case reports and larger clinical trials have demonstrated the safety and efficacy of this drug in patients ranging in age from infants to the elderly and in a variety of races and ethnic groups. Glucarpidase should not be administered within 2 hours of leucovorin, because this agent is a reduced folate which competes with methotrexate for the enzyme and glucarpidase inactivates leucovorin. Side effects of glucarpidase are rare and relatively mild, and include paraesthesia, flushing, nausea, vomiting, pruritus, and headache. Glucarpidase has seen limited use in intrathecal treatment of methotrexate toxicity for which it is also effective. Future applications of this enzyme in chemotherapy continue to be an active area of research.

摘要

2012 年 1 月,葡糖醛酸酶(Voraxaze(®))获得美国食品和药物管理局批准,可用于治疗因肾脏清除能力受损而导致的毒性血浆甲氨蝶呤浓度。甲氨蝶呤是一种抗叶酸药物,已经使用了 60 多年,用于治疗各种癌症。大剂量甲氨蝶呤在治疗白血病和淋巴瘤方面特别有用。然而,即使采用积极的水化和尿液碱化,这种方案也会导致急性肾功能障碍,表现为尿量减少,同时血尿素氮和血清肌酐水平升高。由于甲氨蝶呤主要通过肾脏排泄,这会大大加剧组织损伤。静脉注射葡糖醛酸酶可迅速有效地降低血液中甲氨蝶呤的毒性水平。葡糖醛酸酶是羧肽酶 G2 的重组形式,羧肽酶 G2 是一种细菌酶,可迅速将甲氨蝶呤分解为谷氨酸和 2,4-二氨基-N(10)-甲基蝶啶酸。甲氨蝶呤的代谢产物毒性远低于母体化合物,主要通过肝脏机制排泄。自 20 世纪 90 年代以来,葡糖醛酸酶一直以同情用药的方式提供,各种病例报告和更大规模的临床试验表明,该药物在从婴儿到老年人的各种年龄段的患者以及各种种族和族裔群体中是安全有效的。在给予亚叶酸钙 2 小时内不应给予葡糖醛酸酶,因为亚叶酸钙是一种还原叶酸,它与甲氨蝶呤竞争酶,而葡糖醛酸酶会使亚叶酸钙失活。葡糖醛酸酶的副作用罕见且相对较轻,包括感觉异常、潮红、恶心、呕吐、瘙痒和头痛。葡糖醛酸酶在鞘内治疗甲氨蝶呤毒性方面的应用有限,但它也是有效的。这种酶在化疗中的未来应用仍然是一个活跃的研究领域。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/15a3/3511185/293c743eb330/tcrm-8-403f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验